From the standpoint of this analysis, there appears to be a justification for conducting PD-L1 immunohistochemistry as a routine procedure in UCOGC cases, together with a detailed genetic analysis focused on oncogenic and druggable molecular genetic signatures in all pancreatic cancers, regardless of histological subtype. This evidence concerns the gene CD274 and familial pancreatic carcinoma.